Infections continue to threaten human health. Pathogenic bacteria rapidly develop resistance against antibiotics. Antibiotic resistance is a global, rapidly growing health concern. The World Health Organization (WHO) has declared antibiotic resistance a major threat to global health. Hamlet Biopharma develops novel therapies against infection with the goal to provide a immunotherapy as a molecular framework for the treatment of bacterial infections; much needed to combat antibiotic resistance. One of the main drug candidates, the Interleukin-1 receptor antagonist (IL1-RA), has successfully been used in the clinic to treat bladder pain syndrome and is currently being investigated in controlled Phase II trials.
IL1-receptor antagonists
IL-1 receptor antagonist (Kineret) to treat acute infections and prevent tissue damage
NK1R-inhibitors
A nerve cell receptor antagonist prevents pain and tissue damage during acute infections
RNA Pol II inhibitors
A small molecule from ”nice bacteria” prevents over-activation of immunity and reduces inflammation
IRF7 inhibitors
New molecular tools to inhibit ‘’bad’’ inflammation in infected tissue and reduce the risk of sepsis